This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): estradiol, WC-3011, Estradiol Vaginal Capsule (EVC)
Description: Estradiol is an estrogen steroid hormone. Binding of estradiol to estrogen receptors initiates translocation to the nucleus and and changes in gene expression via estrogen response elements.
Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
Warner Chilcott and Actavis
In May 2013, Actavis and Warner Chilcott announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. The proposed transaction has been unanimously approved by the Boards of Directors of Actavis and Warner Chilcott and is supported by the management teams of both companies.
In October 2013, Actavis announced that it has completed the acquisition of Warner Chilcott in a stock-for-stock transaction valued at approximately $8.5 billion. In connection with the acquisition, Actavis and Warner Chilcott have been combined under a new company incorporated in Ireland, and have adopted the global name Actavis plc. Shares of Actavis plc will trade on the New York Stock Exchange under the ticker symbol ACT. The scheme of arrangement to effect Actavis' acquisition of Warner Chilcott has taken effect today, and Warner Chilcott...See full deal structure in Biomedtracker
Additional information available to subscribers only: